wisowis Posted July 9, 2019 Share Posted July 9, 2019 Seems like a pretty safe spot to park some cash. Trading at book value (70% of which is cash), backed by a NCIB (even during blackout periods), run by a conservative capital allocator (arguably to a fault). Link to comment Share on other sites More sharing options...
snowball82 Posted July 17, 2019 Share Posted July 17, 2019 Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer MONTREAL, July 16, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy1. Knight has the exclusive right to commercialize NERLYNX® in Canada under a license agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) ("Puma"). "The news every woman wants when she has finished her breast cancer treatment is that her cancer is in remission, that she is now cancer free. The approval of NERLYNX® in Canada is even better news." comments Durhane Wong-Rieger, President & CEO of Canadian Organization for Rare Disorders. "Every woman we interviewed who had received NERLYNX® said she was willing to do almost anything to improve the chances, however slight, that her cancer would not return or would not metastasize." According to Canadian Cancer Statistics, breast cancer is the third most commonly diagnosed cancer, accounting for 13% of all cancers.2 It is also the most commonly diagnosed cancer among women.2 Approximately 26,300 women were diagnosed with breast cancer in 2017, and 5,000 died of the disease in the same year.2 A Canadian population-based study estimates that approximately 15 percent of patients with breast cancer have HER 2-positive tumors.3 "The approval of NERLYNX® is a significant treatment advance for patients with early breast cancer," said Jonathan Ross Goodman, Chief Executive Officer of Knight. "After the initial treatment, NERLYNX® further reduces the likelihood of the cancer coming back, giving women the possibility to live cancer free." "The approval of NERLYNX® by Health Canada is a major achievement in helping physicians improve treatment outcomes for their breast cancer patients and we look forward to supporting our partner, Knight Therapeutics, in bringing this novel therapy to the Canadian market," said Puma President and CEO, Alan Auerbach.... Link to comment Share on other sites More sharing options...
wisowis Posted July 18, 2019 Share Posted July 18, 2019 Medison Biotech is still very unhappy with management and has published two press releases in the past 10 days (the latest one this morning). Medison Biotech Considers Requisition of Special Meeting of Shareholders of Knight Therapeutics Inc. (https://www.businesswire.com/news/home/20190718005196/en/) Medison Biotech: Jonathan Goodman Takes Advantage of His Own Failure to Create Value, Enriching Himself at the Expense of the Shareholders of Knight Therapeutics (https://www.businesswire.com/news/home/20190709005514/en/) Link to comment Share on other sites More sharing options...
wisowis Posted August 9, 2019 Share Posted August 9, 2019 Looks like they bought back ~4.6 million shares in July, or ~3% of the company. Link to comment Share on other sites More sharing options...
snowball82 Posted August 16, 2019 Share Posted August 16, 2019 About the pipeline .. Profound got the clearance for Tulsa-Pro https://www.globenewswire.com/news-release/2019/08/16/1903004/0/en/Profound-Medical-Receives-U-S-FDA-510-k-Clearance-for-TULSA-PRO.html Link to comment Share on other sites More sharing options...
wisowis Posted September 8, 2019 Share Posted September 8, 2019 Looks like they bought back ~4.6 million shares in July, or ~3% of the company. I have a stupid question. Their NCIB says "[the company] may purchase up to a daily maximum of 88,853 Shares". Their Q2 update said "The NCIB commenced on July 11, 2019...As at August 6, 2019, the Company has purchased 4,657,235 common shares." Obviously this is well above 88k shares per trading day. I have also noticed they have been buying some large blocks, over 1 million shares in a day. This seems to be contrary to the NCIB - are they allowed to do this? What are the rules governing it? Thanks. Link to comment Share on other sites More sharing options...
no_free_lunch Posted October 9, 2019 Share Posted October 9, 2019 Just finally catching up on this one. Thanks for your posts snowball, NERLYNX was a good find. I don't know the exact number but it has significant potential. I did 5 minutes of google work and found this on it. The article references NERLYNX as neratinib but it's the same product. It's not smoke, the product really works. Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo. https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer Link to comment Share on other sites More sharing options...
snowball82 Posted October 9, 2019 Share Posted October 9, 2019 Just finally catching up on this one. Thanks for your posts snowball, NERLYNX was a good find. I don't know the exact number but it has significant potential. I did 5 minutes of google work and found this on it. The article references NERLYNX as neratinib but it's the same product. It's not smoke, the product really works. Results at 2 years of follow-up showed that treatment with neratinib led to a 51% reduction in the risk invasive disease recurrence or death at 2 years compared with placebo. https://www.targetedonc.com/news/health-canada-approves-extended-adjuvant-neratinib-for-earlystage-hr-breast-cancer Welcome, GUD seems also interested by shopping in Latin America https://www.grupobiotoscana.com/en/ https://braziljournal.com/eurofarma-e-knight-therapeutics-disputam-a-biotoscana Link to comment Share on other sites More sharing options...
snowball82 Posted October 21, 2019 Share Posted October 21, 2019 Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company Executes on Knight’s strategy to build a Rest of World specialty pharmaceutical company and become the partner of choice for top pharmaceutical companies for pan-American (ex-US) in-licensing opportunities Strong regional infrastructure and management team with a unique footprint across 10 countries in Latin America Established and diversified portfolio of innovative products across specialty therapeutic areas Significant organic growth opportunity via robust in-licensing pipeline and a solid platform for future growth via acquisition Grupo Biotoscana generated revenue of BRL 754 million or C$240 million and adjusted EBITDA of BRL 154 million or C$49 million for the last twelve month period ending June 30, 2019 https://www.globenewswire.com/news-release/2019/10/21/1932427/0/en/Knight-Therapeutics-to-Acquire-Grupo-Biotoscana-Establishing-a-Latin-American-Growth-Platform.html Link to comment Share on other sites More sharing options...
no_free_lunch Posted October 21, 2019 Share Posted October 21, 2019 $189m acquisition. They have over half of their cash deployed now. Link to comment Share on other sites More sharing options...
FiveSigma Posted October 21, 2019 Share Posted October 21, 2019 It's CAD $369M for the whole business. Link to comment Share on other sites More sharing options...
snowball82 Posted October 22, 2019 Share Posted October 22, 2019 Not much media coverage so far https://www.gud-knight.com/wp-content/uploads/Biotoscana-Acquisition-IRP-vF-2019.10.21.pdf https://www.theglobeandmail.com/business/article-knight-therapeutics-buys-latin-american-drug-firm-for-418-million-in/ Link to comment Share on other sites More sharing options...
no_free_lunch Posted October 22, 2019 Share Posted October 22, 2019 I went through the slides from knight. I am glad that they are deploying capital (as 5sigma points out, they are now something like 75% deployed) but it's not immediately clear the benefit. They mention access to capital and access to knight's existing contacts. I am just not familiar enough with the industry to determine how much synergy that brings to the table. At least this will silence some of the complaints that knight raised capital and is just sitting on the money and collecting a pay-check. Link to comment Share on other sites More sharing options...
snowball82 Posted October 24, 2019 Share Posted October 24, 2019 Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada http://gudknight.irpass.com/ViewEmail.asp?b=2320&id=184466&p=2170075&I=1237180-i8G3t5c9s4 Link to comment Share on other sites More sharing options...
snowball82 Posted October 29, 2019 Share Posted October 29, 2019 https://www.google.ca/amp/s/business.financialpost.com/pmn/business-pmn/canadas-knight-therapeutics-to-acquire-biotoscana-control-by-nov-29-filing/amp Link to comment Share on other sites More sharing options...
snowball82 Posted November 1, 2019 Share Posted November 1, 2019 Another good news for us, GUD's sharholders. Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada https://www.globenewswire.com/news-release/2019/10/30/1938377/0/en/Knight-and-TherapeuticsMD-Announce-Filing-of-New-Drug-Submission-for-Joyesta-in-Canada.html Link to comment Share on other sites More sharing options...
snowball82 Posted November 13, 2019 Share Posted November 13, 2019 Biotoscana will be soon consolidated with Knight therapeutics.. https://s3.amazonaws.com/mz-filemanager/f78739c6-0e47-4145-8a2e-947b5835a922/758b4ee4-ae60-49a2-b9df-8876b24fef22_GBIO_ER_3Q19_ENG_final.pdf Someone has a a value estimate once 100 % consolidated? Link to comment Share on other sites More sharing options...
snowball82 Posted November 22, 2019 Share Posted November 22, 2019 GUD-Medison resolved https://www.globenewswire.com/news-release/2019/11/21/1951135/0/en/GUD-Medison-Resolved.html Link to comment Share on other sites More sharing options...
snowball82 Posted November 22, 2019 Share Posted November 22, 2019 https://www.biospace.com/article/releases/onconova-therapeutics-announces-exclusive-license-agreement-with-knight-therapeutics-for-rigosertib-in-canada/ Link to comment Share on other sites More sharing options...
wisowis Posted November 22, 2019 Share Posted November 22, 2019 I guess as part of the agreement Medison agreed to take down their noisemaking channels: https://newdayforknight.com/ - dead https://twitter.com/newdayforknight?lang=en - dead Link to comment Share on other sites More sharing options...
snowball82 Posted November 26, 2019 Share Posted November 26, 2019 https://www.globenewswire.com/news-release/2019/11/25/1952253/0/en/Profound-Medical-Announces-Health-Canada-Approval-of-TULSA-PRO.html Link to comment Share on other sites More sharing options...
snowball82 Posted November 26, 2019 Share Posted November 26, 2019 https://www.globenewswire.com/news-release/2019/11/26/1952548/0/en/Knight-and-TherapeuticsMD-Announce-Filing-of-New-Drug-Submission-for-Bijuva-in-Canada.html Link to comment Share on other sites More sharing options...
snowball82 Posted November 29, 2019 Share Posted November 29, 2019 Is tomorrow the closing ? Knight will acquire a 51.21% interest from a controlling shareholder group that includes Advent International and Essex Woodlands (the "Private Transaction") for cash consideration of approximately BRL 596 million or C$189 million(1). The Private Transaction is expected to close by November 29, 2019, subject to the satisfaction of customary closing conditions, and will not be subject to anti-trust approval in Brazil. Link to comment Share on other sites More sharing options...
snowball82 Posted November 29, 2019 Share Posted November 29, 2019 With that news and the new growth profile, GUD’s valuation should be closer to Canadian specialty pharma peers. https://www.globenewswire.com/news-release/2019/11/29/1954221/0/en/Knight-Therapeutics-Announces-Closing-of-Previously-Announced-Acquisition-of-Grupo-Biotoscana.html Link to comment Share on other sites More sharing options...
snowball82 Posted December 20, 2019 Share Posted December 20, 2019 GUD will be added to the index next Monday. http://www.stockwatch.com/News/Item?bid=Z-C%3aGUD-2846883&symbol=GUD®ion=C Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now